by University College London In typical GBS, virus particles stimulate the immune system to produce antibodies that detect both viral surface proteins, but also proteins on the surface of peripheral nerves that cause “auto-immune” destruction. Credit: Dr. Stephen Keddie, UCL A correlation between a first dose of the AstraZeneca vaccine and a small but significant...
(HealthDay)—Receipt of the Ad26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccine is associated with a potential small, but statistically significant, safety concern for Guillain-Barré syndrome (GBS), according to a study published online Oct. 7 in the Journal of the American Medical Association. Emily Jane Woo, M.D., M.P.H., from the U.S. Food and Drug Administration in Silver Spring, Maryland,...
